Fumi Hoshino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fumi Hoshino has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Fumio Sakane
Department of Chemistry, Graduate School of Science, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan
13 shared publications - Chiaki Murakami
Department of Chemistry, Graduate School of Science, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan
9 shared publications Hiromichi Sakai
Department of Biosignaling and Radioisotope Experiment Interdisciplinary Center for Science Research Organization for Research and Academic Information Shimane University Izumo Japan
3 shared publicationsQiang Lu
Department of Chemistry, Graduate School of Science, Chiba University, Chiba, 263-8522, Japan
3 shared publications- Daisuke Takahashi
Department of Pharmaceutical Health Care and Sciences, Kyushu University, Fukuoka 812-8582, Japan
2 shared publications Maho Asami
Department of Chemistry Graduate School of Science Chiba University Chiba Japan
2 shared publications
Latest Publications
- Open Access
- 13 February 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , 103019
Saturated fatty acid– and/or monounsaturated fatty acid–containing phosphatidic acids selectively interact with heat shock protein 27
- 13 February 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , 103019
Open AccessSaturated fatty acid– and/or monounsaturated fatty acid–containing phosphatidic acids selectively interact with heat shock protein 27
Phosphatidylinositol 4,5‐bisphosphate‐specific phospholipase C β1 selectively binds dipalmitoyl and distearoyl phosphatidic acids via Lys946 and Lys951
Phospholipase C (PLC) β1 hydrolyzes 1‐stearoyl‐2‐arachidonoyl (18:0/20:4)‐phosphatidylinositol (PtdIns) 4,5‐bisphosphate to produce diacylglycerol, which is converted to phosphatidic acid (PtdOH), in the PtdIns cycle and plays pivotal roles in intracellular signal transduction. The present study identified PLCβ1 as a PtdOH‐binding protein using PtdOH‐containing liposomes. Moreover, the comparison of the binding of PLCβ1 to various PtdOH species, including 14:0/14:0‐PtdOH, 16:0/16:0‐PtdOH, 16:0/18:1‐PtdOH, 18:0/18:1‐PtdOH, 18:0/18:0‐PtdOH, 18:1/18:1‐PtdOH, 18:0/20:4‐PtdOH, and 18:0/22:6‐PtdOH, indicated that the interaction of PLCβ1 with 16:0/16:0‐PtdOH was the strongest. The PLCβ1‐binding activity of 18:0/18:0‐PtdOH was almost the same as the binding activity of 16:0/16:0‐PtdOH. Furthermore, the binding of PLCβ1 to 16:0/16:0‐PtdOH was substantially stronger than 16:0/16:0‐phosphatidylserine, 16:0/16:0/16:0/16:0‐cardiolipin, 16:0/16:0‐PtdIns, and 18:0/20:4‐PtdIns. We revealed that a PLCβ1 mutant whose Lys946 and Lys951 residues were replaced with Glu (PLCβ1‐KE) did not interact with 16:0/16:0‐PtdOH and failed to localize to the plasma membrane in Neuro‐2a cells. Retinoic acid‐dependent increase in neurite length and numbers was significantly inhibited in PLCβ1‐expressing cells; however, this considerable attenuation was not detected in the cells expressing PLCβ1‐KE. Overall, these results strongly suggest that PtdOHs containing only saturated fatty acids, including 16:0/16:0‐PtdOH, which are not derived from the PtdIns cycle, selectively bind to PLCβ1 and regulate its function.
Phosphatidylinositol 4,5‐bisphosphate‐specific phospholipase C β1 selectively binds dipalmitoyl and distearoyl phosphatidic acids via Lys946 and Lys951
Phospholipase C (PLC) β1 hydrolyzes 1‐stearoyl‐2‐arachidonoyl (18:0/20:4)‐phosphatidylinositol (PtdIns) 4,5‐bisphosphate to produce diacylglycerol, which is converted to phosphatidic acid (PtdOH), in the PtdIns cycle and plays pivotal roles in intracellular signal transduction. The present study identified PLCβ1 as a PtdOH‐binding protein using PtdOH‐containing liposomes. Moreover, the comparison of the binding of PLCβ1 to various PtdOH species, including 14:0/14:0‐PtdOH, 16:0/16:0‐PtdOH, 16:0/18:1‐PtdOH, 18:0/18:1‐PtdOH, 18:0/18:0‐PtdOH, 18:1/18:1‐PtdOH, 18:0/20:4‐PtdOH, and 18:0/22:6‐PtdOH, indicated that the interaction of PLCβ1 with 16:0/16:0‐PtdOH was the strongest. The PLCβ1‐binding activity of 18:0/18:0‐PtdOH was almost the same as the binding activity of 16:0/16:0‐PtdOH. Furthermore, the binding of PLCβ1 to 16:0/16:0‐PtdOH was substantially stronger than 16:0/16:0‐phosphatidylserine, 16:0/16:0/16:0/16:0‐cardiolipin, 16:0/16:0‐PtdIns, and 18:0/20:4‐PtdIns. We revealed that a PLCβ1 mutant whose Lys946 and Lys951 residues were replaced with Glu (PLCβ1‐KE) did not interact with 16:0/16:0‐PtdOH and failed to localize to the plasma membrane in Neuro‐2a cells. Retinoic acid‐dependent increase in neurite length and numbers was significantly inhibited in PLCβ1‐expressing cells; however, this considerable attenuation was not detected in the cells expressing PLCβ1‐KE. Overall, these results strongly suggest that PtdOHs containing only saturated fatty acids, including 16:0/16:0‐PtdOH, which are not derived from the PtdIns cycle, selectively bind to PLCβ1 and regulate its function.
- Open Access
The Roles of Diacylglycerol Kinase α in Cancer Cell Proliferation and Apoptosis
Diacylglycerol (DG) kinase (DGK) phosphorylates DG to generate phosphatidic acid (PA). The α isozyme is activated by Ca2+ through its EF-hand motifs and tyrosine phosphorylation. DGKα is highly expressed in several refractory cancer cells including melanoma, hepatocellular carcinoma, and glioblastoma cells. In melanoma cells, DGKα is an antiapoptotic factor that activates nuclear factor-κB (NF-κB) through the atypical protein kinase C (PKC) ζ-mediated phosphorylation of NF-κB. DGKα acts as an enhancer of proliferative activity through the Raf–MEK–ERK pathway and consequently exacerbates hepatocellular carcinoma progression. In glioblastoma and melanoma cells, DGKα attenuates apoptosis by enhancing the phosphodiesterase (PDE)-4A1–mammalian target of the rapamycin pathway. As PA activates PKCζ, Raf, and PDE, it is likely that PA generated by DGKα plays an important role in the proliferation/antiapoptosis of cancer cells. In addition to cancer cells, DGKα is highly abundant in T cells and induces a nonresponsive state (anergy), which represents the main mechanism by which advanced cancers escape immune action. In T cells, DGKα attenuates the activity of Ras-guanyl nucleotide-releasing protein, which is activated by DG and avoids anergy through DG consumption. Therefore, a DGKα-specific inhibitor is expected to be a dual effective anticancer treatment that inhibits cancer cell proliferation and simultaneously enhances T cell functions. Moreover, the inhibition of DGKα synergistically enhances the anticancer effects of programmed cell death-1/programmed cell death ligand 1 blockade. Taken together, DGKα inhibition provides a promising new treatment strategy for refractory cancers.
Open AccessThe Roles of Diacylglycerol Kinase α in Cancer Cell Proliferation and Apoptosis
Diacylglycerol (DG) kinase (DGK) phosphorylates DG to generate phosphatidic acid (PA). The α isozyme is activated by Ca2+ through its EF-hand motifs and tyrosine phosphorylation. DGKα is highly expressed in several refractory cancer cells including melanoma, hepatocellular carcinoma, and glioblastoma cells. In melanoma cells, DGKα is an antiapoptotic factor that activates nuclear factor-κB (NF-κB) through the atypical protein kinase C (PKC) ζ-mediated phosphorylation of NF-κB. DGKα acts as an enhancer of proliferative activity through the Raf–MEK–ERK pathway and consequently exacerbates hepatocellular carcinoma progression. In glioblastoma and melanoma cells, DGKα attenuates apoptosis by enhancing the phosphodiesterase (PDE)-4A1–mammalian target of the rapamycin pathway. As PA activates PKCζ, Raf, and PDE, it is likely that PA generated by DGKα plays an important role in the proliferation/antiapoptosis of cancer cells. In addition to cancer cells, DGKα is highly abundant in T cells and induces a nonresponsive state (anergy), which represents the main mechanism by which advanced cancers escape immune action. In T cells, DGKα attenuates the activity of Ras-guanyl nucleotide-releasing protein, which is activated by DG and avoids anergy through DG consumption. Therefore, a DGKα-specific inhibitor is expected to be a dual effective anticancer treatment that inhibits cancer cell proliferation and simultaneously enhances T cell functions. Moreover, the inhibition of DGKα synergistically enhances the anticancer effects of programmed cell death-1/programmed cell death ligand 1 blockade. Taken together, DGKα inhibition provides a promising new treatment strategy for refractory cancers.
- Open Access
- 13 August 2021
- Published by Wiley in FEBS Letters
- Vol. 595 (19) , 2479-2492
The SAC1 phosphatase domain of synaptojanin‐1 is activated by interacting with polyunsaturated fatty acid‐containing phosphatidic acids
Although there are many phosphatidic acid (PA) molecular species based on its fatty acyl compositions, their interacting partners have been poorly investigated. Here, we identified synaptojanin‐1 (SYNJ1), Parkinson’s disease‐related protein that is essential for regulating clathrin‐mediated synaptic vesicle endocytosis via dually dephosphorylating D5 and D4 position phosphates from phosphatidylinositol (PI) (4,5)‐bisphosphate, as a 1‐stearoyl‐2‐docosahexaenoyl (18:0/22:6)‐PA‐binding protein. SYNJ1 failed to substantially associate with other acidic phospholipids. Although SYNJ1 interacted with 18:0/20:4‐PA in addition to 18:0/22:6‐PA, the association of the enzyme with 16:0/16:0‐, 16:0/18:1‐, 18:0/18:0‐, or 18:1/18:1‐PA was not considerable. 18:0/20:4‐ and 18:0/22:6‐PAs bound to SYNJ1 via its SAC1 domain, which preferentially hydrolyses D4 position phosphate. Moreover, 18:0/20:4‐ and 18:0/22:6‐PA selectively enhanced the D4‐phosphatase activity, but not the D5‐phosphatase activity, of SYNJ1.
- 13 August 2021
- Published by Wiley in FEBS Letters
- Vol. 595 (19) , 2479-2492
Open AccessThe SAC1 phosphatase domain of synaptojanin‐1 is activated by interacting with polyunsaturated fatty acid‐containing phosphatidic acids
Although there are many phosphatidic acid (PA) molecular species based on its fatty acyl compositions, their interacting partners have been poorly investigated. Here, we identified synaptojanin‐1 (SYNJ1), Parkinson’s disease‐related protein that is essential for regulating clathrin‐mediated synaptic vesicle endocytosis via dually dephosphorylating D5 and D4 position phosphates from phosphatidylinositol (PI) (4,5)‐bisphosphate, as a 1‐stearoyl‐2‐docosahexaenoyl (18:0/22:6)‐PA‐binding protein. SYNJ1 failed to substantially associate with other acidic phospholipids. Although SYNJ1 interacted with 18:0/20:4‐PA in addition to 18:0/22:6‐PA, the association of the enzyme with 16:0/16:0‐, 16:0/18:1‐, 18:0/18:0‐, or 18:1/18:1‐PA was not considerable. 18:0/20:4‐ and 18:0/22:6‐PAs bound to SYNJ1 via its SAC1 domain, which preferentially hydrolyses D4 position phosphate. Moreover, 18:0/20:4‐ and 18:0/22:6‐PA selectively enhanced the D4‐phosphatase activity, but not the D5‐phosphatase activity, of SYNJ1.
- 1 October 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1865 (10) , 158768
Polyunsaturated fatty acid-containing phosphatidic acids selectively interact with L-lactate dehydrogenase A and induce its secondary structural change and inactivation
- 1 October 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1865 (10) , 158768
Polyunsaturated fatty acid-containing phosphatidic acids selectively interact with L-lactate dehydrogenase A and induce its secondary structural change and inactivation
- Open Access
- 16 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (18) , 6794
New Era of Diacylglycerol Kinase, Phosphatidic Acid and Phosphatidic Acid-Binding Protein
Diacylglycerol kinase (DGK) phosphorylates diacylglycerol (DG) to generate phosphatidic acid (PA). Mammalian DGK consists of ten isozymes (α–κ) and governs a wide range of physiological and pathological events, including immune responses, neuronal networking, bipolar disorder, obsessive-compulsive disorder, fragile X syndrome, cancer, and type 2 diabetes. DG and PA comprise diverse molecular species that have different acyl chains at the sn-1 and sn-2 positions. Because the DGK activity is essential for phosphatidylinositol turnover, which exclusively produces 1-stearoyl-2-arachidonoyl-DG, it has been generally thought that all DGK isozymes utilize the DG species derived from the turnover. However, it was recently revealed that DGK isozymes, except for DGKε, phosphorylate diverse DG species, which are not derived from phosphatidylinositol turnover. In addition, various PA-binding proteins (PABPs), which have different selectivities for PA species, were recently found. These results suggest that DGK–PA–PABP axes can potentially construct a large and complex signaling network and play physiologically and pathologically important roles in addition to DGK-dependent attenuation of DG–DG-binding protein axes. For example, 1-stearoyl-2-docosahexaenoyl-PA produced by DGKδ interacts with and activates Praja-1, the E3 ubiquitin ligase acting on the serotonin transporter, which is a target of drugs for obsessive-compulsive and major depressive disorders, in the brain. This article reviews recent research progress on PA species produced by DGK isozymes, the selective binding of PABPs to PA species and a phosphatidylinositol turnover-independent DG supply pathway.
- 16 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (18) , 6794
Open AccessNew Era of Diacylglycerol Kinase, Phosphatidic Acid and Phosphatidic Acid-Binding Protein
Diacylglycerol kinase (DGK) phosphorylates diacylglycerol (DG) to generate phosphatidic acid (PA). Mammalian DGK consists of ten isozymes (α–κ) and governs a wide range of physiological and pathological events, including immune responses, neuronal networking, bipolar disorder, obsessive-compulsive disorder, fragile X syndrome, cancer, and type 2 diabetes. DG and PA comprise diverse molecular species that have different acyl chains at the sn-1 and sn-2 positions. Because the DGK activity is essential for phosphatidylinositol turnover, which exclusively produces 1-stearoyl-2-arachidonoyl-DG, it has been generally thought that all DGK isozymes utilize the DG species derived from the turnover. However, it was recently revealed that DGK isozymes, except for DGKε, phosphorylate diverse DG species, which are not derived from phosphatidylinositol turnover. In addition, various PA-binding proteins (PABPs), which have different selectivities for PA species, were recently found. These results suggest that DGK–PA–PABP axes can potentially construct a large and complex signaling network and play physiologically and pathologically important roles in addition to DGK-dependent attenuation of DG–DG-binding protein axes. For example, 1-stearoyl-2-docosahexaenoyl-PA produced by DGKδ interacts with and activates Praja-1, the E3 ubiquitin ligase acting on the serotonin transporter, which is a target of drugs for obsessive-compulsive and major depressive disorders, in the brain. This article reviews recent research progress on PA species produced by DGK isozymes, the selective binding of PABPs to PA species and a phosphatidylinositol turnover-independent DG supply pathway.
- Open Access
- 20 May 2020
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 22, 100769
Cellular phosphatidic acid sensor, α-synuclein N-terminal domain, detects endogenous phosphatidic acid in macrophagic phagosomes and neuronal growth cones
- 20 May 2020
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 22, 100769
Open AccessCellular phosphatidic acid sensor, α-synuclein N-terminal domain, detects endogenous phosphatidic acid in macrophagic phagosomes and neuronal growth cones
- 1 May 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 525 (4) , 1054-1060
Palmitic acid- and/or palmitoleic acid-containing phosphatidic acids are generated by diacylglycerol kinase α in starved Jurkat T cells
- 1 May 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 525 (4) , 1054-1060
Palmitic acid- and/or palmitoleic acid-containing phosphatidic acids are generated by diacylglycerol kinase α in starved Jurkat T cells
- Open Access
- 5 March 2020
- Published by Wiley in FEBS Letters
- Vol. 594 (11) , 1787-1796
1‐Stearoyl‐2‐docosahexaenoyl‐phosphatidic acid interacts with and activates Praja‐1, the E3 ubiquitin ligase acting on the serotonin transporter in the brain
Serotonin transporter (SERT) is involved in serotonergic system regulation and in the pathophysiology/therapeutics of serotonin‐/SERT‐related diseases such as obsessive‐compulsive disorder, depression, autism, and schizophrenia. We recently revealed that diacylglycerol (DG) kinase (DGK) δ induces ubiquitination/degradation of SERT in a DGK activity‐dependent manner through Praja‐1 E3 ubiquitin‐protein ligase. However, it is still unclear how Praja‐1 activity is regulated by DGKδ. Here, we reveal that 1‐stearoyl‐2‐docosahexaenoyl (18:0/22:6)‐phosphatidic acid (PA) and 18:0/22:6‐DG are simultaneously decreased and accumulated, respectively, in the DGKδ‐knockout mouse brain, indicating that DGKδ selectively phosphorylates 18:0/22:6‐DG to generate 18:0/22:6‐PA. Moreover, we find that 18:0/22:6‐PA selectively binds to Praja‐1 and enhances its activity. These results strongly suggest that 18:0/22:6‐PA generated by DGKδ activates Praja‐1 to degrade SERT in the brain.
- 5 March 2020
- Published by Wiley in FEBS Letters
- Vol. 594 (11) , 1787-1796
Open Access1‐Stearoyl‐2‐docosahexaenoyl‐phosphatidic acid interacts with and activates Praja‐1, the E3 ubiquitin ligase acting on the serotonin transporter in the brain
Serotonin transporter (SERT) is involved in serotonergic system regulation and in the pathophysiology/therapeutics of serotonin‐/SERT‐related diseases such as obsessive‐compulsive disorder, depression, autism, and schizophrenia. We recently revealed that diacylglycerol (DG) kinase (DGK) δ induces ubiquitination/degradation of SERT in a DGK activity‐dependent manner through Praja‐1 E3 ubiquitin‐protein ligase. However, it is still unclear how Praja‐1 activity is regulated by DGKδ. Here, we reveal that 1‐stearoyl‐2‐docosahexaenoyl (18:0/22:6)‐phosphatidic acid (PA) and 18:0/22:6‐DG are simultaneously decreased and accumulated, respectively, in the DGKδ‐knockout mouse brain, indicating that DGKδ selectively phosphorylates 18:0/22:6‐DG to generate 18:0/22:6‐PA. Moreover, we find that 18:0/22:6‐PA selectively binds to Praja‐1 and enhances its activity. These results strongly suggest that 18:0/22:6‐PA generated by DGKδ activates Praja‐1 to degrade SERT in the brain.
- Open Access
- 1 March 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (10) , 2932-2947
Diacylglycerol kinase δ and sphingomyelin synthase–related protein functionally interact via their sterile α motif domains
- 1 March 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (10) , 2932-2947
Open AccessDiacylglycerol kinase δ and sphingomyelin synthase–related protein functionally interact via their sterile α motif domains